Fresenius Kabi USA

Oct 9, 2024 | rxlist.com | John P. Cunha |Fresenius Kabi USA |Lake Zurich

Description for Otulfi Ustekinumab-aauz, a human IgG1κ monoclonal antibody, is a human interleukin-12 and -23 antagonist. Using DNA recombinant technology, ustekinumab-aauz is produced in a Chinese hamster ovary (CHO) cell line. The manufacturing process contains steps for the clearance of viruses. Ustekinumab-aauz is comprised of 1326 amino acids and has an estimated molecular mass that ranges from 148,079 to 149,690 Daltons.

Jun 17, 2024 | rxlist.com | Study AS-I |Fresenius Kabi USA |Lake Zurich

What Is Idacio?

Mar 18, 2024 | rxlist.com | Fresenius Kabi USA

WARNING RISK OF SERIOUS INFECTIONS Patients treated with tocilizumab products including TYENNE are at increased risk for developing serious infections that may lead to hospitalization or death [see WARNINGS AND PRECAUTIONS, ADVERSE REACTIONS]. Most patients who developed these infections were taking concomitant immunosuppressants such as methotrexate or corticosteroids. If a serious infection develops, interrupt TYENNE until the infection is controlled.

Dec 14, 2023 | jamanetwork.com | S. Tu |Rachel H. Goode |Fresenius Kabi USA

Spending on biologics in 2021 represented $260 billion or 46% of all spending on prescription drugs in the US.1 Biosimilar competition can lower prices, but biosimilar entry is often delayed by expansive patent thickets (dozens or hundreds of patents directed toward the same product).

Nov 13, 2023 | jamanetwork.com | Rachel H. Goode |Fresenius Kabi USA |William B. Feldman |S. Tu

In 2021, 46% ($260 billion) of all gross prescription drug spending in the US was on biologic products.1 Patents are government-granted monopolies that last 20 years; by obtaining multiple patents for different aspects of the same product, biologic manufacturers create “patent thickets” that can block or delay biosimilar competition to protect market share.2,3 Although patent gamesmanship by biologic manufacturers has been well documented, a key strategy that has not received sufficient...